Forecast

There is no analyst data available for this company.

News Go to news feed

Freenome hits record high of $14.48

Freenome’s stock climbed to a record high of $14.48, bringing the company’s market capitalization to about $1.5 billion. Over the past year the share price rose 35.27% and currently trades above InvestingPro’s fair-value estimate. TD Cowen, BTIG and Jefferies initiated coverage with buy ratings and $17.00 price targets, highlighting Freenome’s potential in blood-based cancer screening tests and partnerships with Abbott and Roper. Investors should weigh the strong price momentum against signs of possible overvaluation. » More on de.investing.com